Study Summaries
Publications Update # 132
Fate of the IP chemotherapy and now the HIPEC chemotherapy, Mirvetuximab + Bevacizumab in ovarian cancer, should we resect para-aortic nodes in locally advanced cervical cancer (video)
PEACOCC trial: Pembrolizumab in Advanced Clear Cell Cancer (Phase II)
Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.
LARA Phase 2 - Pembrolizumab + Lenvatinib in Recurrent Gynecologic Cancers
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.
GOG 3026: Ribociclib and Letrozole in LGSOC
LACC: Open vs. MIS in Radical Hysterectomy (Final OS)
Minimally invasive radical hysterectomy results in inferior DFS and OS compared to open surgery and is associated with higher recurrence and carcinomatosis. Open surgery should remain the standard of care.
GOG 71: RT +/- Extrafascial Hysterectomy
Routine adjuvant extrafascial hysterectomy after radiation for bulky stage IB cervical carcinoma did not improve OS. Some benefit in local control and PFS was observed, particularly in patients with tumors 4–6 cm.
RAMP-201
Avutometinib 3.2 mg BIW + defactinib 200 mg BID (3-weeks-on/1-week-off) produced clinically meaningful and durable responses with manageable toxicity in recurrent LGSOC
Camrelizumab and Famitinib in Cervical Cancer - Phase 2 Trial
Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.
GOG 3073/ENGOT-72: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA)
Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.